Back to teams

Greg Yap

Partner

Healthcare

greg_yap-BIO

Greg is a partner at Menlo Ventures, where he invests in teams trying to solve major problems in life science and healthcare, with a special interest in novel therapeutic platforms, digital health, and transformative technologies. Since joining in 2017, Greg has led Menlo’s investments in Clear Labs, Delfi Diagnostics, Encoded Therapeutics, Epiodyne, Genesis Therapeutics, H1 Insights, Ophelia Health, Particle Health, Pliant Therapeutics (NASDAQ: PLRX), Senti Biosciences, Scribe Therapeutics and Riva Health. He has also been involved in investments in Benchling, Recursion Pharmaceuticals, and Cofactor Genomics.

Previously, Greg was at Illumina Ventures as entrepreneur-in-residence, where he focused on new investments related to genomics. Prior to entering venture capital, Greg had 20 years of experience in senior executive and entrepreneurial roles in life science and digital health. He was CEO and co-founder of two startups: BlueLight Therapeutics (originally Biodesy), a structure- driven platform & therapeutics company, and PyrAmes, a digital health remote monitoring company. At Roche Diagnostics/Ventana, Greg led a global market-leading cancer diagnostic assay business, serving 20 million patients and delivering $500 million revenue per year. Greg’s operating experience also includes roles as the first healthcare entrepreneur-in-residence at GE; chief operating officer at Cellpoint Diagnostics, an early liquid biopsy startup; vice president and general manager for genetics and molecular diagnostics at Affymetrix, the microarray genomics pioneer; and consultant for McKinsey & Company.

Greg received his bachelor’s degree in molecular biology (summa cum laude) from Princeton University and his MBA from Stanford University’s Graduate School of Business. He is an Aspen Health Innovators Fellow and a member of the Aspen Global Leadership Network. Greg is a Bay Area native and has lived in 11 cities in the area. Greg serves on the board of Outward Bound California and loves all manner of outdoor activities with his family, including backpacking and snowboarding. His favorite sport is basketball.

Greg is a partner at Menlo Ventures, where he invests in teams trying to solve major problems in life science and healthcare, with a special interest in novel therapeutic platforms, digital health, and transformative technologies. Since joining in 2017, Greg has led Menlo’s investments in Clear Labs, Delfi Diagnostics, Encoded Therapeutics, Epiodyne, Genesis Therapeutics, H1 Insights, Ophelia Health, Particle Health, Pliant Therapeutics (NASDAQ: PLRX), Senti Biosciences, Scribe Therapeutics and Riva Health. He has also been involved in investments in Benchling, Recursion Pharmaceuticals, and Cofactor Genomics.

Previously, Greg was at Illumina Ventures as entrepreneur-in-residence, where he focused on new investments related to genomics. Prior to entering venture capital, Greg had 20 years of experience in senior executive and entrepreneurial roles in life science and digital health. He was CEO and co-founder of two startups: BlueLight Therapeutics (originally Biodesy), a structure- driven platform & therapeutics company, and PyrAmes, a digital health remote monitoring company. At Roche Diagnostics/Ventana, Greg led a global market-leading cancer diagnostic assay business, serving 20 million patients and delivering $500 million revenue per year. Greg’s operating experience also includes roles as the first healthcare entrepreneur-in-residence at GE; chief operating officer at Cellpoint Diagnostics, an early liquid biopsy startup; vice president and general manager for genetics and molecular diagnostics at Affymetrix, the microarray genomics pioneer; and consultant for McKinsey & Company.

Greg received his bachelor’s degree in molecular biology (summa cum laude) from Princeton University and his MBA from Stanford University’s Graduate School of Business. He is an Aspen Health Innovators Fellow and a member of the Aspen Global Leadership Network. Greg is a Bay Area native and has lived in 11 cities in the area. Greg serves on the board of Outward Bound California and loves all manner of outdoor activities with his family, including backpacking and snowboarding. His favorite sport is basketball.

Investments

Our Portfolio
benchling
benchling
benchling.com

Benchling is a life sciences R&D cloud platform helping the next generation of scientists make breakthrough discoveries faster than ever before.

Milestones
  • 2012 Founded
  • 2019 Partnered, Series C
benchling_graphic
delfi
delfi
delfidiagnostics.com

Delfi is developing a revolutionary test for early detection of cancer using machine learning on DNA in the blood.

Milestones
  • 2019 Founded
  • 2019 Partnered, Seed
Partner
delfi_graphic
encoded_therapeutics-rectangle
encoded_therapeutics-rectangle
encoded.com

Encoded Therapeutics, a precision gene therapy company, is developing genomics-driven medicines that have the potential to transform the treatment paradigm for severe genetic disorders.

Milestones
  • 2014 Founded
  • 2019 Partnered, Series C
Partner
encoded_therapeutics_graphic
genesistherapeutics.ai

Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.

Milestones
  • 2019 Founded
  • 2020 Partnered, Series A
Partner
genesis_therapeutics_graphic
h1.co

H1's health data platform supports the end-to-end therapeutic development process of medical companies and healthcare systems.

Milestones
  • 2017 Founded
  • 2020 Partnered, Series A
ophelia.com

Ophelia is reinventing drug rehab by making evidence-based treatment private, affordable, and accessible via telemedicine.

Milestones
  • 2019 Founded
  • 2021 Partnered, Series A
ophelia_graphic
recursion NASDAQ: RXRX
recursion
recursion.com

Recursion is discovering transformative new treatments by combining automation, machine learning, and the world’s largest biological image datasets.

Milestones
  • 2013 Founded
  • 2017 Partnered, Series B
  • 2021 IPO; NASDAQ: RXRX
recursion_graphic
riva
riva
rivahealth.com

Riva Health provides a digital cardiology platform designed to give patients a comprehensive, equitable, and accessible way to manage hypertension and heart disease.

Milestones
  • 2013 Founded
  • 2017 Incubated by Menlo Labs
  • 2019 Seed
  • 2021 Series A
Partner
riva_health_graphic
aimmune.com

Aimmune Therapeutics is a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies.

Milestones
  • 2015 IPO
Partner
Aimmune Therapeutics
Aimmune Therapeutics is a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies.
NASDAQ : AIMT
clearlabs.com

Clear Labs offers the only automated next-generation sequencing platform for applications including COVID diagnostics and food safety testing.

Milestones
  • 2014 Founded
  • 2018 Partnered, Series B
Partner
clear_labs_graphic
Clear Labs
Clear Labs offers the only automated next-generation sequencing platform for applications including COVID diagnostics and food safety testing.
clear_labs
cofactorgenomics.com

Cofactor Genomics is a biotech company whose mission is to enable drug development, medical research, and personalized medicine using RNA-based information and technologies.

Milestones
  • 2008 Cofounded
  • 2017 Partnered, Series A
cofactor_genomics_graphic
Cofactor Genomics
Cofactor Genomics is a biotech company whose mission is to enable drug development, medical research, and personalized medicine using RNA-based information and technologies.
cofactor_genomics
curie.bio

Curie.Bio is a seed-stage venture firm and therapeutics accelerator focused on helping founders launch viable therapeutics companies.

Milestones
  • 2021 Founded
  • 2022 Partnered, Series A
Partner
Curie.Bio
Curie.Bio is a seed-stage venture firm and therapeutics accelerator focused on helping founders launch viable therapeutics companies.
curie
earli.com

Earli’s mission is to make cancer a benign experience, by catching and curing it early.

Milestones
  • 2018 Founded
  • 2021 Partnered, Series A
earli_graphic
Earli
Earli’s mission is to make cancer a benign experience, by catching and curing it early.
earli
epiodyne.com

Epiodyne is developing new medicines based on emerging understanding of the role of endorphins in health and disease.

Milestones
  • 2016 Founded
  • 2018 Partnered, Series A
Partner
epiodyne_graphic
Epiodyne
Epiodyne is developing new medicines based on emerging understanding of the role of endorphins in health and disease.
epiodyne
koala.health

Koala is a modern pet healthcare provider with a mail order pharmacy offering for pet medications.

Milestones
  • 2021 Founded
  • 2022 Partnered, Series A
Partner
koala_health_graphic
Koala Health
Koala is a modern pet healthcare provider with a mail order pharmacy offering for pet medications.
koala
particlehealth.com

Particle Health is an API designed for healthcare innovators that gives access to vital medical data.

Milestones
  • 2017 Founded
  • 2020 Partnered, Series A
particle_health_graphic
Particle Health
Particle Health is an API designed for healthcare innovators that gives access to vital medical data.
Particle Health logo
pliantrx.com

Pliant Therapeutics is focused on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.

Milestones
  • 2015 Founded
  • 2018 Partnered, Series B
  • 2020 IPO; NASDAQ: PLRX
Partner
pliant_therapeutics_graphic
Pliant Therapeutics
Pliant Therapeutics is focused on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
NASDAQ: PLRX
pliant_therapeutics 1
scribetx.com

Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying causes of genetic disorders.

Milestones
  • 2018 Founded
  • 2021 Partnered, Series B
Partner
scribe_therapeutics_graphic
Scribe Therapeutics
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying causes of genetic disorders.
scribe_therapeutics
sentibio.com

Led by pioneers in synthetic biology and computation, Senti is pioneering new technology platforms to design synthetic gene circuits for adaptive cell and gene therapies.

Milestones
  • 2016 Founded
  • 2018 Partnered, Series A
  • 2022 IPO; NASDAQ: SNTI
Partner
senti_bio_graphic
Senti Biosciences
Led by pioneers in synthetic biology and computation, Senti is pioneering new technology platforms to design synthetic gene circuits for adaptive cell and gene therapies.
NASDAQ: SNTI